Clinical Trials
35 trialsAPPROACH
Guangdong Association of Clinical Trials
NEOVADE
Guangdong Provincial People's Hospital
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Sichuan University
ANOTHER
Peking Union Medical College Hospital
AERESA
Sun Yat-sen University
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
Fudan University
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ACHIEVE
Zhejiang Cancer Hospital
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
The First Affiliated Hospital of Guangzhou Medical University
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SELECT-2
Hangzhou Normal University
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Kunming Medical University
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
Laibin People's Hospital
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Guangzhou Institute of Respiratory Disease
APPOINT
Shanghai Chest Hospital
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
Tianjin Medical University Cancer Institute and Hospital
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
Shanghai Cancer Hospital, China
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
West China Hospital
MWA
Qianfoshan Hospital
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Tongji Hospital
ATTRACT
Second Affiliated Hospital of Nanchang University
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
Chongqing University Cancer Hospital
ACTIVE
Shanghai Chest Hospital
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
First People's Hospital of Hangzhou
APPEAL
Fudan University
AUTUMN
Tianjin Medical University Cancer Institute and Hospital
ACROSS1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ACROSS2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ANSWER
The First Affiliated Hospital of Guangzhou Medical University